Comprehensive outcomes of on‐ and off‐antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | An, Ji hyun | - |
dc.contributor.author | Shim, Ju Hyun | - |
dc.contributor.author | Kim, Seon-Ok | - |
dc.contributor.author | Choi, Jonggi | - |
dc.contributor.author | Kim, Sang-We | - |
dc.contributor.author | Lee, Danbi | - |
dc.contributor.author | Kim, Kang Mo | - |
dc.contributor.author | Lim, Young-Suk | - |
dc.contributor.author | Lee, Han Chu | - |
dc.contributor.author | Chung, Young-Hwa | - |
dc.contributor.author | Lee, Yung Sang | - |
dc.contributor.author | Suh, Dong Jin | - |
dc.date.accessioned | 2021-07-30T05:28:03Z | - |
dc.date.available | 2021-07-30T05:28:03Z | - |
dc.date.created | 2021-05-14 | - |
dc.date.issued | 2016-09 | - |
dc.identifier.issn | 0146-6615 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/4952 | - |
dc.description.abstract | Although antiviral prophylaxis is essential in hepatitis B patients in the context of cancer chemotherapy, there is little evidence-based consensus regarding the appropriate prevention strategy depending on the underlying type of cancer and viral status. This retrospective study included a comprehensive cohort of 302 hepatitis B surface antigen-positive patients with various cancers undergoing chemotherapy and antiviral prophylaxis. The rates of hepatitis B virus (HBV) reactivation during antiviral therapy (>1 log10 IU/mL increase or positive conversion of serum HBV DNA) and relapse when off antivirals ([re]appearance of HBV DNA >2,000 IU/ml with related alanine aminotransferase elevation) were evaluated, together with the associated risk factors, in a competing risks analysis where cancer death was considered as the competing event. During antiviral prophylaxis, HBV was reactivated in six patients (1.9%), who had leukemia (n = 4) or lymphoma (n = 2) and were treated with lamivudine (n = 4) or entecavir (n = 2). The incidence rate of HBV relapse in 127 off-prophylaxis patients was 21.3% during a median post-antiviral period of 11.7 months. Lymphoma, pre-prophylactic HBV DNA ≥2,000 IU/ml, and age ≥50 years were independent predictors of off-treatment HBV relapse (adjusted hazard ratios 5.25, 3.07, and 0.34, respectively; Ps < 0.05). Antiviral and anticancer drugs, duration of consolidation on antiviral prophylaxis, and HBeAg positivity were not independent predictors. In conclusion, hepatitis B flare-ups are not rare in patients receiving cancer chemotherapy during and after anti-HBV prophylaxis, even when potent antivirals are used. Patients with hematopoietic or lymphoid neoplasms or high viral burdens should receive prolonged and powerful HBV prophylaxis. J. Med. Virol. 88:1576-1586, 2016. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | WILEY-BLACKWELL | - |
dc.title | Comprehensive outcomes of on‐ and off‐antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | An, Ji hyun | - |
dc.identifier.doi | 10.1002/jmv.24512 | - |
dc.identifier.scopusid | 2-s2.0-84977670320 | - |
dc.identifier.wosid | 000385718800014 | - |
dc.identifier.bibliographicCitation | JOURNAL OF MEDICAL VIROLOGY, v.88, no.9, pp.1576 - 1586 | - |
dc.relation.isPartOf | JOURNAL OF MEDICAL VIROLOGY | - |
dc.citation.title | JOURNAL OF MEDICAL VIROLOGY | - |
dc.citation.volume | 88 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 1576 | - |
dc.citation.endPage | 1586 | - |
dc.type.rims | ART | - |
dc.type.docType | 정기학술지(Article(Perspective Article포함)) | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Virology | - |
dc.relation.journalWebOfScienceCategory | Virology | - |
dc.subject.keywordPlus | VIRUS HBV REACTIVATION | - |
dc.subject.keywordPlus | DNA VIRAL LOAD | - |
dc.subject.keywordPlus | CYTOTOXIC CHEMOTHERAPY | - |
dc.subject.keywordPlus | LYMPHOMA PATIENTS | - |
dc.subject.keywordPlus | LAMIVUDINE | - |
dc.subject.keywordPlus | PREVENTION | - |
dc.subject.keywordPlus | ENTECAVIR | - |
dc.subject.keywordPlus | ANTIGEN | - |
dc.subject.keywordPlus | ASSOCIATION | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | hepatitis B virus | - |
dc.subject.keywordAuthor | chemotherapy | - |
dc.subject.keywordAuthor | antiviral prophylaxis | - |
dc.subject.keywordAuthor | cancer | - |
dc.subject.keywordAuthor | relapse | - |
dc.subject.keywordAuthor | reactivation | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1002/jmv.24512 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.